Samsung Biologics held its 13th regular general shareholders’ meeting at the Songdo Convensia in Incheon on March 15. The shareholders’ meeting, attended by approximately 1,500 shareholders both on-site and online, lasted for about 30 minutes starting at 9 a.m.
During the meeting, a total of four agendas were presented and finally approved: the approval of financial statements, the appointment of external directors, the election of audit committee members, and the approval of the directors’ remuneration limit. Seo Seung-hwan, an emeritus professor at Yonsei University, was appointed as a new external director and a member of the audit committee. His term will last for three years starting from that day. Professor Seo served as the Minister of Land, Infrastructure and Transport during the Park Geun-hye administration from 2013 to 2015.
John Rim, CEO of Samsung Biologics, said in his greeting at the shareholders’ meeting, “Although the challenging business environment is expected to continue this year, we will not stop our challenge towards becoming a global top-tier biotech company.” He also emphasized, “We will further enhance customer satisfaction, operational efficiency, quality, and the capabilities of our employees to improve our corporate competitiveness, and all our employees will do their utmost to meet the expectations of our shareholders.”